Targeting of nanoparticles in cancer
Authors:
- Meghna TalekarMTMeghna Talekar
- Jackie KendallJKJackie Kendall
- William DennyWDWilliam Denny
- Sanjay GargSanjay Garg
- 1 November 2011
- journal article
- review article
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 22 (10) , 949-962
Abstract
Anticancer agents continue to be a preferred therapeutic option for several malignancies. Despite their effectiveness, oncologists are continually looking for tumor-specific anticancer agents to prevent adverse effects in patients. Targeting of imaging agents to cancerous tissue is another area that is enthusiastically explored to circumvent some of the drawbacks that current imaging agents possess, including the inability to target small tumor cells, inadequate imaging period, and the risk of renal damage. Formulation scientists have explored nanotechnology-based delivery systems for targeting anticancer agents and tumor-imaging agents to cancer tissue. Targeting with nanotechnology-based delivery systems has been investigated by both passive and active mechanisms with significant clinical success. This review presents a discussion on targeting strategies used for the delivery of nanoparticles by passive and active mechanisms, focusing more specifically on active targeting of nanoparticles using albumin, folic acid, transferrin, and aptamers as targeting ligands.Keywords
This publication has 111 references indexed in Scilit:
- 68Ga-Labeled Inhibitors of Prostate-Specific Membrane Antigen (PSMA) for Imaging Prostate CancerJournal of Medicinal Chemistry, 2010
- The formulation of aptamer-coated paclitaxel–polylactide nanoconjugates and their targeting to cancer cellsBiomaterials, 2010
- Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticlesNature, 2010
- Extracellularly Activated Nanocarriers: A New Paradigm of Tumor Targeted Drug DeliveryMolecular Pharmaceutics, 2009
- Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticlesJournal of Controlled Release, 2008
- Superparamagnetic Iron Oxide Nanoparticle–Aptamer Bioconjugates for Combined Prostate Cancer Imaging and TherapyChemMedChem, 2008
- Aptamer-Targeted Gold Nanoparticles As Molecular-Specific Contrast Agents for Reflectance ImagingBioconjugate Chemistry, 2008
- Folate receptor alpha as a tumor target in epithelial ovarian cancerGynecologic Oncology, 2008
- Physicochemical and Biological Characterization of Targeted, Nucleic Acid-Containing NanoparticlesBioconjugate Chemistry, 2007
- Clinical translation of angiogenesis inhibitorsNature Reviews Cancer, 2002